Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| BJ | BAO_0002670 | |
| assay format component | BAO_0003113 | |
| fluo-8 calcium indicator | BAO_0002672 | |
| LYMP2-010 | BAO_0002673 | |
| scintillation proximity assay | BAO_0000017 | [Scintillation proximity assay (SPA) eliminates the separation step of unbound radioisotopes and is performed using low energy radioisotopes (3H and 125I) as labels, which have short range electron emission. SPA involves the use of microscopic beads which are first coated with a receptor protein of interest and contain a scintillant. When stimulated by the binding of radio-labeled ligand molecules, they emit light, which is detected by the photomultiplier tube. SPA is suitable for high throughput since the protocol has no wash or separation steps.] |
| scintillation counting | BAO_0000405 | [It involves the incorporation of radiolabeled precursors into uniform distribution with a liquid medium capable of converting the kinetic energy of nuclear emissions into light energy. A scintillation counter is used to measure ionizing radiation. The scintillation counter consists of a sensor, called a scintillator, made of transparent crystal or an organic liquid that fluoresces when struck by ionizing radiation. A photomultiplier is then used to measure the light emitted by the sensor and is attached to an electronic apparatus that amplifies and quantifies the radiation signal.] |
| LYMP2-001 | BAO_0002674 | |
| protein substrate and ligand constant | BAO_0000016 | [They are used to express the binding interactions between labeled or unlabeled ligands with protein receptors and include Bmax, Kd, etc.] |
| LYMP2-012 | BAO_0002675 | |
| LYMP2-014 | BAO_0002676 | |
| assay bioassay component | BAO_0003112 | |
| secondary antibody | BAO_0002644 | [The role of an antibody to detect and bind a primary antibody in a sample (cell, tissue, protein blot).] |
| antibody role | BAO_0002642 | [This categorizes the distinct roles played by antibodies in recognizing either the antigen or an antibody itself.] |
| mitotic cell cycle | GO_0000278 | [Progression through the phases of the mitotic cell cycle, the most common eukaryotic cell cycle, which canonically comprises four successive phases called G1, S, G2, and M and includes replication of the genome and the subsequent segregation of chromosomes into daughter cells. In some variant cell cycles nuclear replication or nuclear division may not be followed by cell division, or G1 and G2 phases may be absent.] |
| cell cycle | GO_0007049 | [The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.] |
| isoform | BAO_0002646 | [A quality of a protein that harbors a variation from the native protein (called canonical form), which could arise due to alternative promoter usage, alternative splicing, alternative translation initiation and ribosomal frameshifting.] |
| M phase | GO_0000279 | [A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase.] |
| cell cycle phase | GO_0022403 | [One of the distinct periods or stages into which the cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events.] |
| P2Y12 receptor antagonist | CHEBI_68563 | |
| EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitor | CHEBI_67232 |